Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

Economic Crisis Heightens Financial Fallout For Bereaved
One in five people fall below the official poverty line following the death of their partner. "Hence the recent fall in the value of annuities, savings and investments means an even wider group of older people could face financial difficulties when their partner dies, whether these difficulties are short-lived or longer lasting," says researcher Anne Corden of the Social Policy Research Unit, University of York
generic viagra online
Giving Early Physical And Occupational Therapy To Critically Ill Patients Leads To Better Outcomes
Long-term complications of critical illness include intensive care unit (ICU)-acquired weakness and neuropsychiatric disease - both of which could be related to the immobilisation caused by sedation. An Article published Online First and in an upcoming edition of The Lancet has found that interrupting sedation in the earliest days of treatment to give critically ill patients physical and occupational therapy leads to better outcomes than standard care.
News of the day
Figuring Out Who Will Benefit Most From A New Therapy For Multiple Sclerosis
In a recent phase II clinical trial, the drug alemtuzumab (Campath-1H) was found to be a highly effective treatment for individuals with early relapsing-remitting multiple sclerosis. However, a substantial proportion of the patients treated (30%) went on to develop another autoimmune disease, mostly thyroid autoimmunity. Now, Joanne Jones and colleagues, at the University of Cambridge, United Kingdom, have determined that individuals with higher levels of the soluble factor IL-21 in their blood prior to alemtuzumab treatment were those that went on to develop an autoimmune disease. Further analysis identified a mechanism by which IL-21 contributes to the development of autoimmunity and determined that in some patients the higher levels of IL-21 were genetically predetermined. The authors therefore suggest that measuring levels of IL-21 in the blood of individuals with early relapsing-remitting multiple sclerosis might identify those that would be at greatest risk of developing autoimmunity if treated with alemtuzumab. Terri Laufer and Gregory Wu, at the University of Pennsylvania, Philadelphia, further discuss the importance of this in an accompanying commentary, noting that determining one reason why some patients succumb to autoimmune disease after alemtuzumab treatment, while others do not, is likely to increase enthusiasm for this new therapeutic.
Diagnostics

Oramed Pharmaceuticals Reports Positive Results From A Study Of Oral Insulin Capsule On Type 1 Diabetic Patients

Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of alternative drug delivery systems, today reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients. The completion of this study marks Oramed"s first clinical trial on patients with Type 1 Diabetes Mellitus, whereas, all Oramed"s trials up to date have been conducted on type 2 diabetic patients. This study evaluated safety, tolerability, and food effects in type 1 diabetic patients. Oramed"s oral insulin capsule, (ORMD-0801), was well tolerated by patients and no serious adverse events were observed. The insulin absorption was not affected when given before meal ingestion. Oramed Chief Scientific Officer, Miriam Kidron, PhD., remarked, "These results demonstrate that Oramed"s oral insulin capsule had a good safety profile and was effective on patients with type 1 diabetes when taken prior to a meal." Currently, Oramed is conducting its Phase 2B clinical trial in South Africa, in which the company is evaluating the effects of ORMD-0801 on type 2 diabetic patients. About Oramed Pharmaceuticals Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed"s technology is based on over 25 years of research by top research scientists at Jerusalem"s Hadassah Medical Center. The Company"s corporate and R&D headquarters are based in Jerusalem. Forward-looking statements Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company"s ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company"s filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements. Oramed Pharmaceuticals Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009